Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Single Dose Study of E6130 in Healthy Japanese Males
NCT02902978Phase 1Completed
- Sponsor
- EA Pharma Co., Ltd.
- Start
- Sep 2016
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of E6130 in inflammatory bowel disease (IBD) (2 arms), sponsored by EA Pharma Co., Ltd. Primary endpoint: Treatment Emergent Adverse Events. Started Sep 2016; status: completed.
02
Drugs
E6130
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT02902978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02902978.